PT-141 Peptide: Status, Evidence and Sellers

PT-141, marketed as Vyleesi, is a synthetic cyclic seven-amino-acid analog of alpha-melanocyte-stimulating hormone. The FDA approved bremelanotide in 2019 for hypoactive sexual desire disorder in women who have not reached menopause. It acts on melanocortin receptors in the brain, a different mechanism from flibanserin, the other approved option, and from the PDE5 inhibitors used for erections.

Where sildenafil and tadalafil act peripherally on vascular smooth muscle, this acts in the brain. It targets melanocortin receptors across the hypothalamus and limbic system to shift sexual motivation centrally, so, like flibanserin, it is aimed at desire itself rather than at arousal or lubrication downstream of it.

Compounded bremelanotide is increasingly prescribed off-label to both men and women through telehealth and peptide clinics. Use in men, for low libido or difficulty with arousal, has no large randomized evidence behind it. That application is investigational, and it belongs with a provider who practices sexual medicine rather than one selling peptides.

It agonizes melanocortin receptors, binding MC4R most strongly with secondary activity at MC1R [6]. MC4R appears throughout the hypothalamus, limbic system and brainstem, the regions governing sexual motivation, reward and arousal. Switching it on is thought to lift dopamine and oxytocin signaling within the medial preoptic area, tipping the central balance toward drive.

Acting centrally lets it reach desire and motivation, not only the blood flow downstream, and that is the main distinction from the PDE5 drugs. Melanocortin agonists reliably produce pro-sexual behavior in animals, and what the drug does clinically in humans fits MC4R engagement [6]. The off-target activity at MC1R is not incidental: those receptors sit on melanocytes, and stimulating them repeatedly can darken patches of skin.

Two phase 3 randomized double-blind placebo-controlled trials carry the approval, both enrolling premenopausal women with generalized acquired hypoactive sexual desire disorder [1]. The two co-primary endpoints were change in a desire score and change in distress about low desire. The drug beat placebo on both, by a modest margin, which is what makes this Grade A for the approved indication and separates it from most of what appears on this site. The number of satisfying sexual events, a secondary measure, did not differ from placebo.

A 52-week open-label extension found the benefit holding and the adverse-event profile unchanged, with nothing new emerging on safety beyond what phase 3 had already shown [2]. Subgroups specified in advance (by age, contraception status and baseline severity) all pointed the same direction, which supports the result generalizing rather than resting on one favorable slice [4].

A 2023 pharmacotherapy evaluation placed it in the thin landscape of treatments for female sexual dysfunction, noting that this and flibanserin both deliver modest but real effect sizes with different tolerability, and that patient preference and the nausea risk should drive the choice between them [5].

For men there is mechanistic rationale and small early-phase data, and no published phase 3 trial. Off-label use in men leans on MC4R biology and clinical extrapolation. A prescriber should say that out loud before writing it, rather than letting the approval for a different population imply evidence that does not exist.

Per the FDA label, Vyleesi is one 1.75 mg auto-injector dose into the abdomen or thigh, used as needed and given 45 minutes or more ahead of sex. The label allows one dose in any 24-hour period and advises against going above eight a month [7]. It is approved only for premenopausal women whose low desire is acquired and generalized (HSDD) [7].

Compounded bremelanotide and uses outside that label, including in men, have no approved dose, and this page does not give one. Compounded products are not reviewed by the FDA for equivalent potency or sterility, so if you use one, use a state-licensed pharmacy filling an individual prescription and a prescriber who is monitoring you.

Nausea dominates. Across the phase 3 trials and the long-term safety program about 40% of those treated reported it, against fewer than 2% given placebo [3]. Headache and flushing turned up often too. It typically starts within an hour of injection and passes within a few hours. Taking ondansetron beforehand did not reduce it in a study the label describes.

Blood pressure also rises temporarily, by up to about 6 mmHg systolic and 3 diastolic, peaking two to four hours after a dose and settling within twelve hours in most people [3]. That makes it contraindicated in anyone with known cardiovascular disease or uncontrolled hypertension. And repeated dosing can darken patches of the face, gums or breasts through that MC1R activity. That change may be permanent, so it should be discussed before the first injection.